CHEN-HUA LIUCHUN-JEN LIUTUNG-HUNG SUHUNG-CHIH YANGCHUN-MING HONGTAI-CHUNG TSENGPEI-JER CHENDING-SHINN CHENJIA-HORNG KAO2021-03-092021-03-0920180815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042270551&doi=10.1111%2fjgh.13912&partnerID=40&md5=1c979ded0e67f55b6da553b1740c938bhttps://scholars.lib.ntu.edu.tw/handle/123456789/551082Background and Aim: The real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV-1b) patients. The study aimed to evaluate the antiviral responses of PrOD-based regimens for HCV-1b patients in Taiwan. Methods: The study performed a retrospective analysis of 103 HCV-1b patients receiving PrOD with or without ribavirin (RBV) for 12?weeks. Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events. The pre-specified characteristics related to sustained virologic response 12?weeks off therapy (SVR12) were compared. Results: At treatment week 4, 100 of 102 patients (98.0%) had serum HCV RNA level <?25?IU/mL. The SVR12 was achieved in 101 of 103 patients (98.1%, [95% confidence interval: 93.2–99.5%]). All except one (99.0%) patients tolerated treatment well without treatment interruption. One cirrhotic patient discontinued treatment at week 1 due to hepatic decompensation. Twenty-four patients (23.3%) had ? grade 2 elevation in total bilirubin levels, and 21 of them (87.5%) had indirect type hyperbilirubinemia. The stratified SVR12 rates were comparable in terms of sex, age, body mass index, prior treatment experience, hepatitis B virus surface antigen status, RBV usage, baseline and week 2 viral load, renal function, and hepatic fibrosis stage. Conclusions: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without RBV are efficacious and generally well tolerated for treatment of HCV-1b patients in Taiwan. ? 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd[SDGs]SDG3alanine aminotransferase; aspartate aminotransferase; bilirubin; bilirubin glucuronide; dasabuvir; hepatitis B surface antigen; ombitasvir plus paritaprevir plus ritonavir; ribavirin; robatrol; virus RNA; ABT-267; ABT-333; ABT-450; anilide; antivirus agent; carbamic acid derivative; macrocyclic compound; ribavirin; ritonavir; sulfonamide; uracil; acute kidney failure; adult; aged; alanine aminotransferase blood level; antiviral therapy; arthralgia; Article; ascites; aspartate aminotransferase blood level; body mass; body weight gain; chronic hepatitis C; coughing; decompensated liver cirrhosis; diarrhea; drug efficacy; drug safety; drug withdrawal; dyspnea; fatigue; female; headache; Hepatitis C virus subtype 1b; human; hyperbilirubinemia; insomnia; kidney function; liver cell carcinoma; liver cirrhosis; liver fibrosis; major clinical study; male; nausea; priority journal; pruritus; retrospective study; side effect; sustained virologic response; Taiwan; treatment duration; treatment interruption; very elderly; virus load; analogs and derivatives; chronic hepatitis C; combination drug therapy; genetics; genotype; Hepacivirus; middle aged; safety; treatment outcome; virology; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Viral Loadjournal article10.1111/jgh.13912287625412-s2.0-85042270551